Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Plus Lenvatinib and Chemotherapy in First-Line Extrapulmonary Neuroendocrine Carcinoma
NCT07738159Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Primary completion
- Aug 2030
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by West China Hospital of Sichuan University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07738159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738159.